Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

2(40.0%)

N/A

2(40.0%)

Phase 2

1(20.0%)

5Total

Phase 3(2)

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT01432080Phase 2Terminated

Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant

Role: collaborator

NCT00342316Not ApplicableCompleted

Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia

Role: collaborator

NCT02504047Not ApplicableCompleted

Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units

Role: collaborator

NCT00438958Phase 3Completed

Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Role: lead

NCT01217723Phase 3Unknown

Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation

Role: collaborator

All 5 trials loaded